They need it for their early june usa biotech networking conference.
- trial fully enrolled
- no safety issues
- all participants still on
- tox study done with zero issues
- efficacy likely to show stabalisation or dare to say improvement
- works with exon skipping
- yet to partner with anyone
- inflammation now better understood to be key driver for best treatment outcomes
- show us the money
When US tox study due, page-7
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
